About 300 reports

  • DIABETES DRUGS MARKET, GLOBAL, OVERALL PHARMACEUTICAL INDUSTRY PIPELINE
  • Pipeline Landscape Assessment

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Diabetes
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Causes of gastroparesis

These muscles contract to break up the food and lead to its movement through the gastrointestinal tract.

  • Diabetes
  • Forecast
  • Cadila Healthcare Ltd
  • GlaxoSmithKline plc
  • Valeant Pharmaceuticals International, Inc.

Home-Made Diets Commercial Enteral Formulas Elemental Formulas Oligomeric Formulas Polymeric Formulas Special Formulas Pulmonary Formulas Liver Formulas Renal Formulas Diabetes Formulas Gastrointestinal Dysfunction Formulas Immuno-modulatory Formulas Contraindications to Enteral Feeding Com

  • Diabetes
  • United States
  • World
  • Company Sales
  • Market Segment

BRAIN STROKE The blood flow disturbance in the gastrointestinal tract can lead to serious illness such as arterial or venous occlusion or hypotonia, peptic ulcer, and gastrointestinal tract ischemia, which may lead to extensive necrosis of the intestine.

  • Diabetes
  • World
  • GE Healthcare Limited
  • Koninklijke Philips N.V.
  • Medtronic, Inc.
  • Vendor landscape
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • ASTRAZENECA
  • MERCK

Its products target the gastrointestinal, metabolic, genitourinary, musculoskeletal, inflammation, ophthalmic, neurology, and pulmonary therapeutic areas.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

The company' s products mainly deal in segments such as respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease (CVMD), oncology, infection, neuroscience, and gastrointestinal.

  • Diabetes
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Nu clear receptor, 1, 3%
  • DIABETES AND OBESITY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR ERTUGLIFLOZIN

As previously outlined, Xenical is a gastrointestinal lipase inhibitor that acts specifically in the lumen of the stomach and small intestine.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Pipeline analysis

Sotagliflozin is a small molecule and exhibits its mechanism by inhibiting SGLT-##, which helps absorb glucose and galactose in the gastrointestinal (GI) tract, and SGLT-##, which helps in glucose reabsorption by the kidney.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • the illness. Consequently, patients in this region are highly engaged and well informed about their medical condition.

Diseases covered under such programs include most cardiovascular & gastrointestinal disorders, asthma, breast cancer, chronic-obstructive pulmonary disease, coronary heart disease & heart failure, diabetes etc.

  • Diabetes
  • World
  • Market Size
  • Animas Corporation
  • Insulet Corporation
  • Conclusion
  • 9 Appendix

GASTROINTESTINAL EVENTS SUCH AS NAUSEA AND DIARRHEA OCCURRED MOST FREQUENTLY.

  • Diabetes
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.

IV iron bypasses the problem of gastrointestinal absorption and poor compliance.

  • Diabetes
  • World
  • Actavis plc
  • AMAG Pharmaceuticals, Inc.
  • Vifor Pharma

The company' s major therapeutic areas INCLUDE IMMUNOLOGY, CVD, DIABETES, GASTROINTESTINAL DISEASE, INFECTIOUS DISEASES, MUSCULOSKELETAL DISEASE, NEUROSCIENCE, ONCOLOGY, OPHTHALMOLOGY, AND RESPIRATORY DISEASES.

  • Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

The gastrointestinal tract is the route of choice for the administration of most drugs, regardless of their weight and molecular structure.

  • Diabetes
  • World
  • Market Size
  • AstraZeneca PLC
  • Becton Property Group
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • REGULATION OF GLUCOSE METABOLISM

The post-meal rise in blood glucose and the presence of certain gastrointestinal hormones stimulate the production of insulin.

  • Diabetes
  • DexCom, Inc.
  • LifeScan, Inc.
  • Medtronic, Inc.
  • Roche Group
  • PROPORTION AND NUMBER OF PEOPLE (20-79 YEARS) LIVING WITH DIABETES WHO ARE UNDIAGNOSED, 2015
  • ADULTS AGED 15-74 YEARS

The gastrointestinal tract is the route of choice for the administration of most drugs, regardless of their weight and molecular structure.

  • Diabetes
  • Abbott Laboratories, Inc.
  • Becton Property Group
  • Johnson & Johnson
  • Medtronic, Inc.

GENEREX BIOTECHNOLOGY Advantage of Oral-Lyn Improving compliance: The alternatives to injectable insulin include insulin patches, insulin pumps, inhaled insulin, oral formulations designed to restrict insulin digestion in the gastrointestinal tract, and oral formulations for buccal delivery

  • Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Oramed Pharmaceuticals Inc.
  • MARKET ANALYSIS 2016

Improving compliance: The alternatives to injectable insulin include insulin patches, insulin pumps, inhaled insulin, oral formulations designed to restrict insulin digestion in the gastrointestinal tract, and oral formulations for buccal delivery.

  • Diabetes
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

However, the need for frequent dosing and the drug' s gastrointestinal side effects are a challenge in terms of patient adherence.

  • Diabetes
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Novo Nordisk Group
  • VIVUS, Inc.

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Diabetes
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

It also offers assays for breast, colon, pancreatic, testicular, gastrointestinal, liver, ovarian, and prostate cancer; cardiac (CVDs); fertility/ pregnancy; infectious disease (next-generation blood screening and hematology); and metabolic (liver and kidney function).

  • Diabetes
  • World
  • Forecast
  • Bayer AG
  • Roche Group

gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

  • Diabetes
  • Asia
  • China
  • Demand
  • Zhejiang Expressway Co., Ltd.

GI = gastrointestinal.

  • Diabetes
  • World
  • Cepheid
  • Hologic, Inc.
  • Roche Group

THE ENDOBARRIER GASTROINTESTINAL LINER IS TRANSORALLY PLACED IN THE GASTROINTESTINAL TRACT IN ORDER TO BYPASS A PORTION OF THE INTESTINE.

  • Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.

Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monit

  • Diabetes
  • World
  • Abbott
  • ARKRAY, Inc.
  • Bayer AG
  • An overview of pancreas and diabetes

THESE AGENTS ARE ASSOCIATED WITH REDUCED RATES OF HYPOGLYCEMIA, MODERATE AND CONTINUOUS WEIGHT LOSS, AND GASTROINTESTINAL SIDE-EFFECTS SUCH AS NAUSEA AND VOMITING.

  • Diabetes
  • Forecast
  • Insulet Corporation
  • Medtronic, Inc.
  • Roche Group
  • RISK FACTORS & PREVENTION
  • INTRODUCTION

Gastrointestinal complications of diabetes.

  • Chronic Disease
  • Diabetes
  • Pathology
  • Europe
  • Investigators Information

THE INCIDENCES OF THE PRE-SPECIFIED GASTROINTESTINAL AES OF ABDOMINAL PAIN, DIARRHEA, AND NAUSEA WERE LOW AND DID NOT DIFFER BETWEEN GROUPS.

  • Diabetes
  • Drug Discovery And Development
  • World
  • Merck & Co., Inc.
  • Novartis AG

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.